The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).
 
Samuel Rosner
No Relationships to Disclose
 
Lavanya Sivapalan
No Relationships to Disclose
 
Marianna Zahurak
No Relationships to Disclose
 
Rohit Thummalapalli
No Relationships to Disclose
 
Roni Rayes
No Relationships to Disclose
 
Sydney Connor
No Relationships to Disclose
 
Khaled Sanber
No Relationships to Disclose
 
Joshua E. Reuss
Honoraria - AstraZeneca/MedImmune; Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Guardant Health; Personalis; Sanofi
Research Funding - Genentech/Roche (Inst); Nuvalent, Inc. (Inst); Verastem (Inst)
 
Gavin Pereira
No Relationships to Disclose
 
Kellie Nicole Smith
Stock and Other Ownership Interests - ManaT Bio
Honoraria - Adaptive Biotechnologies
Patents, Royalties, Other Intellectual Property - ManaT Bio
 
Valsamo Anagnostou
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Delfi Diagnostics (Inst); Personal Genome Diagnostics (Inst)
 
Stephen Broderick
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dilon Technologies (I); Dilon Technologies (I)
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
Speakers' Bureau - DAVA Oncology; Genentech/Roche
 
Julie R. Brahmer
Honoraria - Janssen
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech; GlaxoSmithKline; Incyte; Merck; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); RAPT Therapeutics (Inst); Spectrum Pharmaceuticals (Inst)
Other Relationship - Bristol-Myers Squibb; Merck; Regeneron
 
Kristen A. Marrone
Honoraria - AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Lilly; Janssen; Mirati Therapeutics; Puma Biotechnology; Regeneron
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Mirati Therapeutics
 
Jonathan Spicer
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Flame Biosciences; Genentech/Roche; Guardant Health; Janssen Oncology; Merck; Novartis; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Patrick M. Forde
Consulting or Advisory Role - Amgen; Ascendis Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CureVac; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; Fosun Pharma; G1 Therapeutics; Genentech; Gilead Sciences; ITeos Therapeutics; Janssen; Merck; Novartis; Regeneron; Sanofi; Surface Oncology; Synthekine; Teva
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst); Regeneron